CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I, Open-label Multi-dose Two-part Study to Characterize the Effects of a Strong CYP3A4 Inhibitor and a Strong CYP3A4 Inducer on the Steady-State Pharmacokinetics of Tazemetostat (EPZ-6438) in Subjects With Advanced Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04537715
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:50.795934+00:00
Published At: 2024-08-26T00:00:00+00:00
Record Updated At: 2025-02-19
Results Posted At: 2024-08-26
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["All Malignancies", "Advanced Malignancies", "Hematologic Malignancy", "Solid Tumor", "Follicular Lymphoma (FL)", "Non-Hodgkin Lymphoma (NHL)", "Diffuse Large B-Cell Lymphoma (DLBCL)", "Epithelioid Sarcoma (ES)", "Synovial Sarcoma", "Renal Medullary Carcinoma", "Mesothelioma", "Rhabdoid Tumor"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-02-19"
protocolSection.identificationModule.nctId: "NCT04537715"
protocolSection.identificationModule.officialTitle: "A Phase I, Open-label Multi-dose Two-part Study to Characterize the Effects of a Strong CYP3A4 Inhibitor and a Strong CYP3A4 Inducer on the Steady-State Pharmacokinetics of Tazemetostat (EPZ-6438) in Subjects With Advanced Malignancies"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2024-08-26"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.